Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,145.03 USD
-5.16 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1,150.00 +4.97 (0.43%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 3,953.60 | 4,338.40 | 8,075.30 | 3,513.20 | 2,115.80 |
Depreciation/Amortization & Depletion | 421.00 | 341.40 | 286.20 | 235.90 | 210.30 |
Net Change from Assets/Liabilities | -94.10 | -243.30 | -1,916.50 | -1,503.60 | -200.50 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 313.50 | 578.40 | 636.30 | 372.60 | 304.40 |
Net Cash From Operating Activities | 4,594.00 | 5,014.90 | 7,081.30 | 2,618.10 | 2,430.00 |
Property & Equipment | -718.60 | -590.10 | -551.90 | -614.60 | -429.60 |
Acquisition/ Disposition of Subsidiaries | -54.90 | -230.30 | 0.00 | 0.00 | 0.00 |
Investments | -2,203.80 | -1,937.40 | -4,832.80 | 544.00 | -1,598.20 |
Other Investing Activities | -207.80 | -1,026.80 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -3,185.10 | -3,784.60 | -5,384.70 | -70.60 | -2,027.80 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1,790.10 | -1,009.00 | -1,005.80 | -3,952.40 | -252.10 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 1,981.90 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -1,790.10 | -1,009.00 | -1,005.80 | -1,970.50 | -252.10 |
Effect of Exchange Rate Changes | -0.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -381.60 | 221.30 | 690.80 | 577.00 | 150.10 |
Cash at Beginning of Period | 3,119.40 | 2,898.10 | 2,207.30 | 1,630.30 | 1,480.20 |
Cash at End of Period | 2,737.80 | 3,119.40 | 2,898.10 | 2,207.30 | 1,630.30 |
Diluted Net EPS | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 |
Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 2,154.30 | 722.00 | 3,953.60 | 2,794.00 | 1,786.20 |
Depreciation/Amortization & Depletion | 234.80 | 114.10 | 421.00 | 308.00 | 202.60 |
Net Change from Assets/Liabilities | -468.00 | 440.50 | -94.10 | -32.70 | 159.60 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -54.60 | 235.90 | 313.50 | 435.00 | 241.60 |
Net Cash From Operating Activities | 1,866.50 | 1,512.50 | 4,594.00 | 3,504.30 | 2,390.00 |
Property & Equipment | -294.30 | -133.90 | -718.60 | -467.20 | -291.20 |
Acquisition/ Disposition of Subsidiaries | -5.00 | 0.00 | -54.90 | -51.10 | 0.00 |
Investments | -1,886.70 | -1,525.30 | -2,203.80 | -2,454.90 | -2,209.60 |
Other Investing Activities | -58.30 | -27.90 | -207.80 | -145.70 | -121.80 |
Net Cash from Investing Activities | -2,244.30 | -1,687.10 | -3,185.10 | -3,118.90 | -2,622.60 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -431.00 | 47.10 | -1,790.10 | -1,344.00 | -936.70 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -431.00 | 47.10 | -1,790.10 | -1,344.00 | -936.70 |
Effect of Exchange Rate Changes | -0.80 | -0.50 | -0.40 | -0.60 | -0.40 |
Net Change In Cash & Equivalents | -809.60 | -128.00 | -381.60 | -959.20 | -1,169.70 |
Cash at Beginning of Period | 2,737.80 | 2,737.80 | 3,119.40 | 3,119.40 | 3,119.40 |
Cash at End of Period | 1,928.20 | 2,609.80 | 2,737.80 | 2,160.20 | 1,949.70 |
Diluted Net EPS | 12.41 | 6.27 | 10.21 | 8.89 | 8.50 |